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Acorus calamus is a plant commonly used as a traditional herbal medicine and possesses the wide range
of pharmacological applications. The present study investigated the diuretic and antiurolithiatic activities
of an ethanolic extract of Acorus calamus L. (Family: Araceae) rhizome (EEAC). For diuretic activity, three
doses of EEAC (250, 500 and 750 mg/kg) were studied, and measurement of the urinary volume and
electrolytes (Naþ and Kþ) concentration were taken as evaluation parameters. On the other hand,
ethylene glycol induced urolithiasis (0.75% v/v in drinking water for 28 days) was used to study the
antiurolithiatic effect of EEAC at the oral dose of 750 mg/kg in male Wistar albino rats. CYSTONE
(750 mg/kg, p.o.) was used as a standard reference drug in the present study. After completion of the 28-
days respective treatments, the level of various urolithiatic promoters in the biological samples (urine,
serum and kidney homogenate) and renal function were used as criteria for assessing the antiurolithiatic
effect of EEAC. Results indicate that, the EEAC (750 mg/kg, p.o.) produced signiﬁcant increase in urine
volume (p < 0.001) and urinary excretion of Naþ and Kþ electrolytes (p < 0.05) in a pattern comparable to
that of furosemide. In ethylene glycol induced urolithiatic model, EEAC signiﬁcantly (p < 0.05) decreased
excretion and deposition of various urolithiatic promoters as compared to urolithiatic control in a pattern
comparable to that of CYSTONE. The EEAC supplementation also prevents the impairment of renal
functions. The antiurolithiatic mechanism is mediated possibly through diuretic and nephroprotective
actions of the active compounds of rhizomes.
Copyright © 2016, Center for Food and Biomolecules, National Taiwan University. Production and hosting
by Elsevier Taiwan LLC. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Urolithiasis is one such disease that after extensive research in
the ﬁeld of urology has remained incurable in allopathy. It is a
process of stone formation which occurs either in the kidney
(commonly known as nephrolithiasis) and or in any part of the
urinary tract, including the ureters (known as ureteral stone) and
bladder (bladder stone). Urolithiasis has an important effect on the
health care system with a prevalence of >10% and an expected
recurrence rate of ~50%.1 The worldwide incidence of urolithiasis is
quite high, andmore than 80% of urinary calculi are calcium oxalatef Complementary Medicine,
0, Australia. Tel.: þ61 2 4620
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molecules, National Taiwan Unive
ons.org/licenses/by-nc-nd/4.0/).(CaOx) stones alone or CaOx mixed with calcium phosphate.2
Epidemiological studies revealed that the nephrolithiasis is more
prevalent in men (12%) than in women (6%) and is more prevalent
between the ages of 20e40 in both sexes.3
Various sophisticated investigations, including radiological and
other laboratory techniques are not sufﬁciently helpful to elucidate
the exact causes and mechanisms of stone formation.4 However,
various factors that might be responsible for the formation of stone
have been extensively studied recently. It is believed that when the
urine becomes saturated with insoluble materials because of
excretion rates are excessive which leads to crystals formation and
aggregation to form a stone.5 Urolithiasis needs both preventive
and curative therapy. Currently, there are no satisfactory drugs in
modern medicine, which can dissolve the stone and therefore
physicians remain to be depending on alternative systems of
medicine for better relief.5 The other medical management of
urolithiasis mainly involves the surgical removal of stones. Tech-
niques such as extracorporeal shock wave lithotripsy (ESWL) andrsity. Production and hosting by Elsevier Taiwan LLC. This is an open access article
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tion of recurrence of the stone. Moreover, they cause side effects
such as hemorrhage, hypertension, tubular necrosis and subse-
quent ﬁbrosis of the kidney.6 In the traditional systems of medicine,
most of the remedies were taken from plants and that were proved
to be useful in various disease conditions. Noteworthy, traditional
herbal medicines are efﬁcacious and have lesser side effects
compared to modern drugs and also reduce the recurrence rate of
the renal stone. The vast Ayurvedic literature claims a number of
plants to be useful in the treatment of urinary stones; still many
plants need to be exploited for their pharmacological actions.7
Acorus calamus L. (Family: Araceae) commonly known as ‘sweet
ﬂag', a well-knownmedicinal plant of the Indian medicinal system,
has been used traditionally in a wide variety of ailments.8e10 The
major chemical constituents of A. calamus rhizome are alkaloids,
ﬂavonoids, gums, lectins, mucilage, phenols, quinone, saponins,
sugars, tannins, and triterpenes.11 The essential oil components of
rhizomes comprise mainly a-asarone, b-asarone, g-asarone, iso-
eugenol acorenone, iso-acorone, Z-sesquilavandulol and dehydroxy
isocalamendiol.12 In laboratory experiments, the rhizomes of A.
calamus have been reported various pharmacological activities
which include antidiabetes,13 antiproliferative and immunosup-
pressive,14 antidiarrheal,15 hypolipidemic,16 antioxidant,17
diuretic,18 and nephroprotective19 activities. As per the indige-
nous system of medicine, A. calamus has been used for the treat-
ment of insomnia, epilepsy, hysteria, loss of memory, remittent
fevers and neurosis.20 The rhizomes of the plant possess diuretic
and antioxidant properties. Furthermore, the rhizome of the plant
has also a signiﬁcant nephroprotective effect. Based on this litera-
ture background, we hypothesized that A. calamus rhizomes might
be effective in urolithiatic condition. However, there is a lack of
scientiﬁc study reporting its antiurolithiatic activity in experi-
mental induced renal stone formation in a laboratory animal.
Hence, in the present study, the ethanolic extract of A. calamus
evaluated against ethylene glycol induced renal calculi in Wistar
albino rats.2. Material and methods
2.1. Identiﬁcation, collection and extraction of plant material
The rhizomes of A. calamus were purchased from the Sanjivani
Ayurvedic Store, Rajkot, India and were identiﬁed by Prof. Vishal
Muliya, Taxonomist, Department of Botany, Christ College, Rajkot,
India. The rhizomes of A. calamus were powdered with a me-
chanical grinder to obtain a coarse powder. Equal quantity of
powder was passed through 40 mesh sieve to get a coarse powder
of desired particle size. The powdered material was subjected to
successive extraction with ethanol (95% v/v) in a Soxhlet apparatus
at 60 C. Appearance of colorless solvent in the siphon tube was
taken as the end point of extraction. The extracts were concen-
trated to ¾ of its original volume by distillation. The concentrated
extracts were taken in a china dish and evaporated on a thermostat
controlled water bath until it forms a thick paste. The extract was
dried and stored in a refrigerator at 4 C in a glass bottle throughout
the study. The dried, crude concentrated extracts were labeled as
EEAC. The yield was found to be 12.8% w/w.2.2. Chemicals
Ethylene glycol was purchased from Sulab laboratory, Baroda,
India. Various kits for biochemical estimation of urine and serum
were purchased from Span Diagnostics, Surat, India. CYSTONE was
purchased from Shrinath Pharmacy, Rajkot, India. All otherchemicals and reagents used were of analytical grade and procured
from approved chemical suppliers.
2.3. Preliminary phytochemical analysis
The EEAR was subjected to qualitative analysis of the various
phytoconstituents by standard methods.21 It revealed the presence
of carbohydrates, glycosides, alkaloids, tannins and phenolic
compounds.
2.4. Animals
Healthy adult Wistar male rats weighing 150e200 g of equiva-
lent age groups, were procured from Zydus Research Center,
Ahmedabad, India. Upon arrival, the rats were randomly housed
under hygienic conditions in polypropylene cages (3 per cage) to
minimize isolation stress, if any. The animal facility was well-
ventilated and maintained at an ambient temperature of
24± 2 C having 50e60% relative humidity with 12-h light and dark
cycle. The animals were acclimatized to the laboratory conditions
for one week prior to the experiments and provided with standard
diet (JS Exports, Kanpur India) and water ad libitum. The use and
care of the animals in this experimental protocol was approved by
the Institutional Animal Care and Ethics Committee (Approval
Number: SJT/025-2011) following guidelines of the Committee for
the Purpose of Control and Supervision of Experiments on Animal
(CPCSEA), Government of India.
2.5. Preliminary phytochemical screening
Qualitative chemical tests were conducted for preliminary
phytochemical screening of the ethanolic extract of A. calamus to
know the nature of phytoconstituents present in extract.
2.6. Diuretic activity of EEAC in rats
The method described by Lipschitz was employed for the
assessment of the diuretic activity of EEAC.22 The animals were
fasted for 18 h prior to experiment allowing only water during the
fasting period. Thirty (30) healthy albino Wistar rats were selected
and divided into ﬁve groups consisting of six rats in each group.
Group I: Normal control group; received sodium carboxymethyl
cellulose (CMC, 0.5% w/v) orally at the dose of 10 ml/kg. Group II:
Standard group: received furosemide orally at the dose of 15mg/kg.
Group III to Group V served as test groups and received EEAC orally
at the dose of 250, 500 and 750 mg/kg respectively. After 1 h of
respective treatments, the animals were kept in metabolic cages
individually for the collection of urine. The urine was collected for
7 h after the dose was administered. The bladder was emptied by
pulling the base of the tail of each rat. Diuretic assay parameters
such as total urine volume and urinary excretion of Naþ and Kþ
were measured in collected urine. The total difference in the
collected urine volume of the respective test group was compared
with the standard and control group. Furthermore, the ratio of
urine volume of the test group and the control groupwas calculated
as a diuretic index. Estimation of Naþ and Kþ content of the urine
samples treated with EEAC at different doses as well as other
groups was done by ﬂame photometry.23 The urinary Naþ and Kþ
content of the respective test groups were also compared with that
of control and standard group.
2.7. Ethylene glycol-induced urolithiasis model in rats
Ethylene glycol-induced urolithiasis model was used to assess-
ing the urolithiatic activity in albino Wistar rats.24,25 Animals were
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normal control group maintained on a standard laboratory diet and
drinking water ad libitum and treated with vehicle (1% CMC) for 28
days. All remaining groups received calculi inducing treatment for
28 days, comprised 0.75% v/v ethylene glycol in drinking water. The
urolithiatic control group received vehicle (1% sodium CMC) by oral
gavage once daily for 28 days. The EEAC group treated with 750mg/
kg of EEAC by oral gavage once daily for 28 days, while the positive
control group treated with 750 mg/kg of CYSTONE by oral gavage
once daily for 28 days.2.7.1. Collection and analysis of urine
After 28 days of an experimental period, all animals were kept in
individual metabolic cages with the hydration of 15 ml of water,
and urine samples of 24 h were collected. Animals had free access
to drinking water during the urine collection period. A drop of
concentrated hydrochloric acid was added to the collected urine
and stored at 4 C. After urine collection, total urinary excretion of
calcium, oxalate, phosphate and uric acid were measured by
various biochemical kits (Span Diagnostics, Surat, India) according
to manufacturer's instruction.2.7.2. Serum analysis
After urine collection on 29th-day blood was collected retro-
orbitally under mild anesthetic condition and animals were sacri-
ﬁced by cervical decapitation. Serum was separated by centrifu-
gation at 12,000 rpm for 5 min and analyzed for calcium,
phosphate, urea, uric acid and creatinine by using various
biochemical kits (Span Diagnostics, Surat, India) according to the
manufacturer's instruction.2.7.3. Preparation of kidney homogenate and biochemical
estimation
The abdomen was cut open to remove both kidneys from each
animal. Isolated kidneys were cleaned from extraneous tissue and
rinsed with ice-cold physiological saline and dried at 80 C in a hot
air oven. A sample of 100mg of the dried kidneywas boiled in 10ml
of 1N hydrochloric acid for 30 min and homogenized. The ho-
mogenate was centrifuged at 2000 rpm for 10 min, and the su-
pernatant was separated. The supernatant was analyzed for
calcium, phosphate, oxalate and uric acid by using various
biochemical kits (Span Diagnostics, Surat, India) according to the
manufacturer's instruction.2.8. Statistical analysis
All values were expressed as mean ± SEM (standard error of
mean) of six rats (n ¼ 6). The statistical analysis was done by
analysis of variance (ANOVA) followed by Dunnett's multiple
comparison tests. The value of p < 0.05 was considered as sig-
niﬁcant. The statistical software used was GraphPad Prism
(version 5.0).Table 1
Effect of EEAC on urine volume, diuretic index, urinary Naþ and Kþ excretion in normal
Group Dose (p.o.) Volume of urine (ml) Diuret
Control 10 ml/kg 1.88 ± 0.18 e
Furosemide 15 mg/kg 4.02 ± 0.17* 2.14
EEAC 1 250 mg/kg 1.78 ± 0.13 0.95
EEAC 2 500 mg/kg 2.21 ± 0.14 1.18
EEAC 3 750 mg/kg 3.78 ± 0.11* 2.01
All values are expressed as mean ± SEM of 6 rats (n ¼ 6), *p < 0.001, when compared to3. Results
3.1. Preliminary phytochemical screening
The EEAC was subjected to qualitative analysis of the various
phytoconstitutents by standard methods. It revealed the presence
of carbohydrates, glycosides, alkaloids, tannins and phenolic
compounds.3.2. Effect of EEAC on diuresis
EEAC did not produce a signiﬁcant increase in urine volume at
the dose of 250 and 500 mg/kg, while EEAC at the dose of 750 mg/
kg showed signiﬁcantly (p < 0.001) increase in the urine volume
(with good diuretic index; >1.5) as compared to a normal control
group. Furthermore, the effect of EEAC (750 mg/kg) was also
comparable with that of the standard diuretic agent, furosemide
(Table 1). The EEAC at the dose of 750 mg/kg showed signiﬁcantly
(p < 0.05) increase in urinary electrolytes Naþ and Kþ excretion as
compared to the control group. Furosemide also signiﬁcantly
(p < 0.05) enhanced the urinary Naþ and Kþ excretion when
compared to the control group (Table 1).3.3. Effect of EEAC on ethylene glycol-induced urolithiasis
3.3.1. Effect of EEAC on body weight, urine volume, and kidney
weight
Administration of ethylene glycol (0.75% v/v in drinking water)
produced signiﬁcant (p < 0.05) reduction in body weight of uro-
lithiatic control rats. These changes were signiﬁcantly (p < 0.001)
prevented in CYSTONE and EEAC treated groups as compared to
urolithiatic control rats. Signiﬁcant (p < 0.001) decrease in 24-h
urine volume (ml) was observed in urolithiatic control rats while
EEAC showed signiﬁcant (p < 0.001) improvement in urinary
output as compared to urolithiatic control animals. Furthermore,
there was signiﬁcant (p < 0.05) increase inwet weight of kidney (g)
in urolithiatic control rats, which was signiﬁcantly (p < 0.05) pre-
vented by EEAC and CYSTONE. The same scenario was observed in
dry kidney weight. (Table 2).3.3.2. Effect of EEAC on urine analysis
The urinary excretion of various urolithiatic promoters such as
calcium, oxalate, phosphate and uric acid was measured. There
were signiﬁcant (p < 0.05) increase in the urinary excretion of
calcium, oxalate, phosphate and uric acid in the urine of urolithiatic
control rats as compared to normal control rats. However, supple-
mentationwith EEAC displayed a signiﬁcant (p < 0.05) reduction in
urinary excretion of calcium, oxalate, phosphate and uric acid as
compared to urolithiatic control rats. Furthermore, these results are
also comparable with the standard drug, CYSTONE that also
signiﬁcantly (p < 0.05) reduced urolithiatic promoters in the uri-
nary excretion of urolithiatic control rats (Table 3).rats.
ic index Naþ (mEq/L) Kþ (mEq/L) Naþ/Kþ
62.50 ± 8.73 9.59 ± 0.79 6.51
94.64 ± 10.13* 13.88 ± 0.80** 6.81
66.25 ± 5.58 9.45 ± 0.64 7.01
77.41 ± 9.23 11.16 ± 0.59 6.93
82.47 ± 3.80* 12.06 ± 0.47* 6.83
control, p.o. ¼ per oral, mEq/L ¼ Milli equivalents per liter.
Table 2
Effect of EEAC on various physical parameters of ethylene glycol induced urolithiasis in Wistar rats.
Group Dose (p.o.) Physiological parameter
% Change in body weight Diuresis (ml) Wet kidney weight (g) Dry kidney weight (g)
Normal control 10 ml/kg 5.80 ± 0.74 9.39 ± 0.75 1.425 ± 0.12 0.854 ± 0.02
Urolithiatic control 10 ml/kg 8.20 ± 1.01# 6.91 ± 0.57# 2.29 ± 0.05# 1.02 ± 0.03#
EEAC 750 mg/kg 3.79 ± 0.30** 16.90 ± 0.65** 1.772 ± 0.05** 0.991 ± 0.04
CYSTONE 750 mg/kg 3.86 ± 0.35** 18.17 ± 0.80** 1.677 ± 0.06** 0.882 ± 0.03*
All values are expressed as mean ± SEM of 6 rats (n ¼ 6); #p < 0.05 when compared to normal control, *p < 0.05 and **p < 0.001 when compared to urolithiatic control,
p.o. ¼ per oral.
Table 3
Effect of EEAC on urinary excretion of various urolithiatic factors of ethylene glycol induced urolithiasis in Wistar rats.
Group Dose (p.o.) Urine parameter (mg/24 h)
Calcium Oxalate Phosphate Uric acid
Normal control 10 ml/kg 5.10 ± 0.41 0.69 ± 0.12 6.07 ± 0.28 3.65 ± 0.19
Urolithiatic control 10 ml/kg 9.73 ± 0.35# 2.21 ± 0.25# 10.28 ± 0.32# 6.16 ± 0.11#
EEAC 750 mg/kg 6.34 ± 0.20* 1.04 ± 0.18* 7.18 ± 0.23* 4.24 ± 0.11*
CYSTONE 750 mg/kg 6.23 ± 0.29* 0.95 ± 0.15* 7.21 ± 0.21* 4.29 ± 0.13*
All values are expressed as mean ± SEM of 6 rats (n ¼ 6), #p < 0.001 when compared to normal control and * p < 0.001 when compared to urolithiatic control, p.o. ¼ per oral.
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Renal stone induction causes impairment of renal functions and
resulting in the serum elevation of glomerular and tubular damage
markers. In the present study, the rats treated with ethylene glycol
alone showed signiﬁcantly (p < 0.01) elevation of various serum
markers including calcium, phosphate, uric acid, blood urea nitro-
gen and creatinine compared with the normal control rats. How-
ever, EEAC along with ethylene glycol produced signiﬁcantly
(p < 0.05 and p < 0.01 and p < 0.001) reduction in serum calcium,
phosphate, uric acid, blood urea nitrogen and creatinine compared
with the ethylene glycol alone-treated controls and the results are
comparable with the value observed with the standard drug, CYS-
TONE (Table 4).
3.3.4. Effect of EEAC on kidney homogenate analysis
The deposition of urolithiatic promoters in the renal tissues,
namely calcium, oxalate, phosphate and uric acid were recorded.
However, those promoters were found to be signiﬁcantly (p < 0.05)
higher in the renal tissue of ethylene glycol alone treated uro-
lithiatic control rats compared to the normal control rats. EEAC
treatment with ethylene glycol produced signiﬁcantly (p < 0.01 and
p < 0.001) reduction in the deposition of urolithiatic promoters
compared with urolithiatic control rats (Table 5).
4. Discussion
In the present study, we demonstrated diuretic and anti-
urolithiatic activities of an ethanolic extract of A. calamus (EEAC) in
experimentally induced animal models. Initially, the diuretic ac-
tivity of three different doses (250, 500 and 750mg/kg) of EEAC hasTable 4
Effect of EEAC on serum concentration of various urolithiatic factors of ethylene glycol in
Group Dose (p.o.) Serum parameter (mg/dl)
Calcium Phosph
Normal control 10 ml/kg 7.22 ± 0.35 3.35 ±
Urolithiatic control 10 ml/kg 9.42 ± 0.29# 4.40 ±
EEAC 750 mg/kg 7.53 ± 0.40*** 3.47 ±
CYSTONE 750 mg/kg 7.27 ± 0.31*** 3.32 ±
All values are expressed as mean ± SEM of 5 rats (n¼ 6), #p < 0.01 when compared to nor
control, p.o. ¼ per oral.been carried out to establish an effective dose for chronic anti-
urolithiatic activity. The administration of a single oral dose of EEAC
(250, 500 and 750 mg/kg) markedly increases diuresis as indicated
by increase urinary ﬂow. Additionally, acute treatment with EEAC
also increases dose dependent excretion of both Naþ and Kþ elec-
trolytes. However, a signiﬁcant diuretic activity has been observed
with the highest dose (750 mg/kg) which also showed marked
kaliuresis and natriuresis. Moreover, the increase in the ratio of
concentration of excreted Naþ and Kþ for the EEAC indicates that
the EEAC increases Naþ excretion to a greater extent than Kþwhich
is essential quality of a good diuretic agent with lesser hyper-
kalaemic side effect. Furosemide, a standard diuretic used in this
study also increased urine volume and excretion of Naþ and Kþ
suggested that stimulation of diuresis by EEAC could be similar to
that of furosemide. Such rapid and acute diuretic activity of EEAC
may be due to active phytoconstituents such as alkaloids, steroids,
tannins, phenolic compound, terpenoids and ﬂavonoids, which are
present in EEAC detected by phytochemical analysis in our study.
In the present study, we also examined the protective effects of
EEAC in ethylene glycol induced renal calculi in albino Wistar rat.
Urinary supersaturation of various stone-forming elements is
commonly considered to be one of the causative factors in the stone
formation.26 Renal calcium oxalate (CaOx) crystal deposition
induced by ethylene glycol is the most appropriate animal model
that is frequently used to mimic the stone formation in humans.
Previously reported studies showed that after the 28 days period of
ethylene glycol (0.75% v/v) administration in the drinking water of
laboratory animals signiﬁcantly cause renal stone formation that
mainly consist CaOx by increasing the urinary concentration of
oxalate.27e31 Furthermore, Robinson et al has demonstrated thatduced urolithiasis in Wistar rats.
ate Uric acid Urea Creatinine
0.16 7.18 ± 0.28 7.18 ± 0.28 0.50 ± 0.05
0.17# 8.38 ± 0.19# 8.38 ± 0.19# 1.65 ± 0.06#
0.22* 7.34 ± 0.15** 7.34 ± 0.15* 0.72 ± 0.04**
0.21** 7.28 ± 0.17*** 7.28 ± 0.17** 0.61 ± 0.04**
mal control and * p < 0.05, **p < 0.01 and ***p < 0.001 when compared to urolithiatic
Table 5
Effect of EEAC on various urolithiatic factors in kidney homogenate of ethylene glycol induced urolithiasis in Wistar rats.
Group Dose (p.o.) Kidney homogenate parameter (mg/100 mg kidney weight)
Calcium Oxalate Phosphate Uric acid
Normal control 10 ml/kg 2.29 ± 0.14 0.72 ± 0.05 1.38 ± 015 1.80 ± 0.05
Urolithiatic control 10 ml/kg 4.62 ± 0.16# 1.47 ± 0.12# 2.36 ± 0.16# 2.67 ± 0.26#
EEAC 750 mg/kg 2.60 ± 0.20** 0.75 ± 0.06** 1.48 ± 0.14* 1.72 ± 0.08*
CYSTONE 750 mg/kg 2.56 ± 0.12** 0.70 ± 0.06** 1.26 ± 0.15** 1.61 ± 0.09**
All values are expressed as Mean ± SEM (n¼ 6); #p < 0.01 when compared to normal control, *p < 0.01 and **p < 0.001 when compared to urolithiatic control, p.o.¼ per oral.
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days in laboratory rats did not produce any carcinogenicity or
gastric ulcer.32 Ethylene glycol is readily absorbed in the intestine
and is metabolized in the liver to oxalate leading to hyperoxaluria.
The oxalate precipitates in the urine as CaOx due to its poor solu-
bility. CaOx crystals and high oxalate levels in nephrons damage
epithelial cells, inducing heterogeneous crystal nucleation and
causing aggregation of crystals.33,34 The urinary system of male rats
also resembles that of humans therefore it is rational to use this
disease model to examine the protective effects of chronic treat-
ment of EEAC. To our knowledge, this is the ﬁrst study to use
ethylene glycol induced renal calculi rat model in investigating the
protective effects of the EEAC on urolithiasis.
Weight loss observed in urolithiatic rats is due to anorexia and
disturbances in carbohydrates, proteins or fat metabolism that is
affected by the ingestion of ethylene glycol. The present study
showed a signiﬁcant reduction in body weight of urolithiatic rats
that was effectively suppressed by EEAC treatment. Furthermore,
urine volume was also signiﬁcantly reduced in urolithiatic rats that
might be due to crystal and stone formation in renal tissue. It is
reported that the increase in the urinary excretion volume facili-
tates the removal of small crystals and reduces the chance of these
crystals to grow or aggregate.35 However, supplementation of EEAC
markedly improves the urinary excretion volume (diuresis) and
thereby hastens the process of dissolving the pre-formed stones
and prevention of new stone formation in the urinary system. An
increase in dry and wet kidney weight is also observed in uro-
lithiatic control rats due to deposition of various urolithiatic pro-
moters in the kidney. Conversely, EEAC decreases kidney weight by
suppressing the deposition of various urolithiatic promoters in the
kidney.
It is well recognized that hyperoxaluria is a far more signiﬁcant
risk factor in the pathogenesis of renal stones than hypercalciuria.36
The changes in urinary oxalate levels are relatively much more
signiﬁcant and have about 15-fold greater effect than those of
calcium.25,37,38 In the present study, ethylene glycol treatment
markedly increased the oxalate level in the urine of urolithiatic rats
that was reduced by chronic EEAC treatment. The decrease in ox-
alate excretion by EEAC was might be either due to the inhibition of
the formation of oxalate, or the EEAC might interfere with oxalate
metabolism. Moreover, literature indicates that the plant extract
rich in tannins, ﬂavonoids and isoﬂavonoids can lead to relaxation
of smooth muscle of the urinary and biliary tract which could
facilitate the expulsion of stones from the kidney and diminished
the size of calculi in rats.31,39 The phytochemical analysis of EEAC in
our study and previously reported studies9,11,12,40 have already
conﬁrmed that EEAC is the rich source of tannins, ﬂavonoids, and
isoﬂavonoids.
The ethylene glycol is metabolized to acidic metabolites like
hippuric acid, oxalic acid, formic acid and benzoic acids which
cause metabolic acidosis and further produced defects in proximal
tubule HCO3 reabsorption. Acidosis produces renal calcium leak
associated with the gut absorption of calcium and bone calcium
release that leads to hypercalciuria and hypercalcemia.41e43Moreover, increased urinary calcium is a factor favoring the
nucleation and precipitation of CaOx or calcium phosphate from
urine and subsequent crystal growth.44 A similar change was
observed in the present study, the administration of ethylene glycol
cause increased calcium level in urine, serum and kidney homog-
enate thereby promoting the formation of CaOx stones. The treat-
ment of EEAC reduced calcium in the urine, serum, and kidney
homogenate in urolithiatic rats and thereby prevents the formation
and aggregation of stone. An increase in urinary phosphate is
observed in urolithiatic rats. Increased urinary phosphate excretion
along with oxalate stress seems to provide an environment
appropriate for stone formation by forming calcium phosphate
crystals, which epitaxially induces calcium oxalate deposition.45
Treatment of EEAC restores phosphate level in serum, urine and
kidney homogenate of urolithiatic rats, thus reducing the risk of
stone formation.
The present study also showed that there were an increased
calcium and oxalate levels in kidney homogenate by ethylene glycol
treatment in urolithiatic rats. In other words, ethylene glycol
increased the deposition of calcium and oxalate contents in renal
tissue that was signiﬁcantly attenuated by EEAC administration.
The increase in calcium level in renal tissue might be due to the
increased bioavailability of nitric oxide (NO) which in turn activates
cGMP (30, 50-cyclic guanosine monophosphate) that controls the
increase in intracellular calcium levels. Literature indicates that NO
donors have the capacity to control the intracellular rise in calcium
levels.30,31,46 EEAC could decrease the calcium level by increasing
the bioavailability of NO to sequester calcium through the cGMP
pathway. Furthermore, ethylene glycol also increased oxalate pro-
duction by increasing substrate availability for various oxalate
synthesizing enzymes such as glycolic acid oxidase and lactate
dehydrogenase, which catalyze the oxidation and reduction of
glyoxalate into glycolate and oxalate.38 These changes facilitate the
hyperoxaluria and subsequent CaOx crystal adherence and reten-
tion in renal tubules.47 Hence, EEAC might effectively control the
level of oxalate by inhibiting the synthesis of oxalate.
In urolithiasis, the glomerular ﬁltration rate (GFR) decreases due
to the obstruction to the outﬂow of urine by stones in the urinary
system. Due to this, the waste products, particularly nitrogenous
substances such as urea, uric acid and, creatinine get accumulated
in blood.48 In the present study, elevation of serum urea, uric acid
and, creatinine have been noted which were restored by treatment
with EEAC and thereby improved renal functions in urolithiatic
condition.
5. Conclusion
In conclusion, EEAC showed remarkable protection from
ethylene glycol induced urolithiasis by strongly suppressing various
urolithiatic promoters in serum, urine, and kidney tissue. Further-
more, EEAC has a signiﬁcant diuretic action that can further help to
ﬂush those promoters in urine and also increases the dissolution of
pre-formed stones and prevention of new stone formation (recur-
rence). Thus, the present ﬁnding emphasizes that the rhizomes of A.
H. Ghelani et al. / Journal of Traditional and Complementary Medicine 6 (2016) 431e436436calamus possess potential medicinal value and beneﬁcial in the
prevention of renal stone. Further studies need to be undertaken to
explain detail mechanism(s) of action of A. calamus rhizomes.
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